# US 2025/0152636 A1 · Cardiac stem cells for cardiac repair

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152636 A1
- Document ID: US20250152636A1
- Status: Published application
- Kind: A1
- Application number: 18/955,452
- Filed: 2024-11-21
- Published: 2025-05-15
- Earliest claimed: 2014-05-14
- Assignees: University of Maryland, Baltimore
- Applicants: University of Maryland, Baltimore
- Inventors: Sunjay KAUSHAL
- Web page: https://patentgrep.com/patent/US20250152636A1

## CPC

- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/1891: {Angiogenesic factors; Angiogenin}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/195: {Chemokines, e.g. RANTES}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to a subject in need thereof.

## Claims

### Claim 1

A composition, comprising neonatal cardiac cells which have been manipulated to increase expression of SDF-1α, VEGF-A, PGDF-B, IL-6, FGF-2, or combinations thereof, and wherein the neonatal cardiac cells are
(a) positive for protein expression of c-kit and Nkx2.5,
(b) negative for protein expression of ISL1; and
(c) negative for protein expression of CD31, CD106, CD140b, or CD86.

### Claim 2

A composition comprising human, neonatal cardiac stem cells and one or more pharmaceutically acceptable carriers, wherein the human, neonatal cardiac stem cells:
(a) positive for protein expression of c-kit, SDF-1α, VEGF-A, PGDF-B, IL-6, FGF-2, and Nkx2.5,
(b) negative for protein expression of ISL1; and
(c) negative for protein expression of CD31, CD106, CD140b, or CD86.

### Claim 3 (depends on 1)

An exosome derived from the neonatal cardiac stem cells of claim 1, wherein the exosome is CD63+.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising of claim 1, comprising the neonatal cardiac stem cells and a pharmaceutically acceptable carrier.

### Claim 5

A method of treating a cardiac medical condition in a subject in need thereof, comprising administering to the subject a composition comprising human, neonatal cardiac stem cells and one or more pharmaceutically acceptable carriers, wherein the human, neonatal cardiac stem cells:
(a) positive for protein expression of c-kit, SDF-1α, VEGF-A, PGDF-B, IL-6, FGF-2, and Nkx2.5,
(b) negative for protein expression of ISL1; and
(c) negative for protein expression of CD31, CD106, CD140b, or CD86,
whereby the cardiac medical condition is treated.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cells are genetically engineered.

### Claim 7 (depends on 6)

The method of claim 6, wherein the genetically engineered cells comprise an exogenous nucleic acid construct that encodes SDF-1α, VEGF-A, PDGF-A, IL-6, or FGF-2.

### Claim 8 (depends on 5)

The method of claim 5, wherein the method reduces inflammation in the subject.

### Claim 9 (depends on 5)

The method of claim 5, wherein the composition is administered into a damaged myocardial tissue of the subject.

### Claim 10 (depends on 5)

The method of claim 5, wherein the subject is a mammal.

### Claim 11 (depends on 10)

The method of claim 10, wherein the mammal is a human.

### Claim 12 (depends on 5)

The method of claim 5, wherein the cells are further negative for protein expression of CD34, CD80, SSEA4, SSEA3, or a combination thereof.

### Claim 13 (depends on 5)

The method of claim 5, wherein the cells are further positive for protein expression of FKBP4, CXCL3, and PRDX5.

### Claim 14 (depends on 5)

The method of claim 5, wherein the cells are further positive for protein expression of SOD2, HSP90AB1, HSPA8, HSP90AA1, HNRNPA2B1, or HLA-B, or any combination thereof.

### Claim 15 (depends on 5)

The method of claim 5, wherein the cells are further positive for protein expression of GDF15, HNRNPC, HSPAIA, NPMI, PAFAHIB2, RBM8A, SET, STIP1, SUMO1, or XPO1, or any combination thereof.

### Claim 16 (depends on 5)

The method of claim 5, wherein the cells secrete cytokines, pro-angiogenic factors, growth factors, transcription factors, or miRNAs, or any combination thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cells secrete VEGF-A, HGF, SCD, SDF-1α, ANG-1, PGDF-B, IL-6, or FGF-2, or any combination thereof.

### Claim 18 (depends on 5)

The method of claim 5, wherein the cells have allogeneic properties.

### Claim 19 (depends on 5)

The method of claim 5, wherein the neonatal cardiac stem cells are from an infant which is less than 30 days old.

### Claim 20 (depends on 5)

The method of claim 5, wherein the cardiac medical condition is heart failure, cardiomyopathy, or congenital heart disease.

### Claim 21 (depends on 5)

The method of claim 5, wherein the method improves cardiac function.

### Claim 22 (depends on 5)

The method of claim 5, wherein the method attenuates ventricular remodeling.

### Claim 23

A composition comprising genetically engineered, human, neonatal cardiac stem cells and one or more pharmaceutically acceptable carriers, wherein the genetically engineered, human, neonatal cardiac stem cells:
(a) are positive for protein expression of c-kit and Nkx2.5,
(b) negative for protein expression of GATA4, CD31, and Isl1, and
(c) comprise an exogenous nucleic acid construct that encodes SDF-1α, VEGF-A, PDGF-A, IL-6, or FGF-2.

### Claim 24

A pharmaceutical composition comprising a therapeutically effective amount of a conditioned medium derived from neonatal cardiac stem cells exposed to one or more heat shock response inducers in a culture medium in vitro, wherein the neonatal cardiac stem cells have been sorted for c-kit+ and expanded in vitro and have the following characteristics: c-kit+, CD90+, CD44+, CD105+, CD31−, CD34−, CD45−, Nkx2.5+, tryptase negative, and SSEA4−.

### Claim 25

A method of treating a cardiac medical condition in a subject in need thereof, comprising administering to the subject a composition comprising human, neonatal cardiac stem cells and one or more pharmaceutically acceptable carriers, wherein the human, neonatal cardiac stem cells:
(a) are positive for protein expression of c-kit and Nkx2.5, and
(b) negative for protein expression of GATA4, CD31, and Isl1,
whereby the cardiac medical condition is treated.

### Claim 26

A method of treating a cardiac medical condition in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a human, neonatal cardiac stem cell (nCSC) secretome and a pharmaceutically acceptable carrier; wherein the secretome comprises SOD2, HSPA8, HSP90AA1, HSP90AB1, and HNRNPA2B1; whereby the cardiac medical condition is treated.
